Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Elimusertib in Advanced Pancreatic and Ovarian Cancer
NCT04616534Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elimusertib in pancreatic cancer (PC), ovarian cancer and solid tumor, sponsored by National Cancer Institute. Primary endpoints: Number of Patients on Treatment With Related Adverse Events up to 315 days, Maximum Tolerated Dose up to 285 days and 4 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
elimusertib
03
Conditions
pancreatic cancer (PC)ovarian cancersolid tumor
Beyond the preview
Go deeper on NCT04616534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616534.